STOCK TITAN

Skye Bioscience - SKYE STOCK NEWS

Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.

Skye Bioscience (SKYE) is a clinical-stage biopharmaceutical innovator developing targeted therapies through cannabinoid receptor modulation. This page serves as the definitive source for verified company announcements, research milestones, and financial updates.

Investors and researchers will find timely updates on clinical trials, regulatory developments, and strategic partnerships. Our curated collection includes earnings reports, pipeline progress for nimacimab (peripheral CB1 inhibitor), and scientific presentations - all organized for efficient due diligence.

Key focus areas include metabolic disorder therapeutics, antibody-based drug development, and clinical safety data. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining accessibility for both specialist and general audiences.

Bookmark this page for structured access to SKYE's evolving position in biopharmaceutical innovation, with particular emphasis on obesity treatment research and peripheral endocannabinoid system modulation.

Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) receives FDA clearance to initiate Phase 2 clinical trial of nimacimab, a peripherally-acting CB1 inhibitor, targeting obesity and chronic kidney disease. Nimacimab shows promising safety and tolerability in Phase 1b study, with encouraging trends in exploratory biomarkers. The molecule offers potential as a single or combination therapy for metabolic conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.44%
Tags
-
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) plans to develop nimacimab, a monoclonal antibody targeting the endocannabinoid system, for weight loss and obesity treatment. The Company filed an IND application with the FDA for a Phase 2 study in patients with obesity and chronic kidney disease. Nimacimab's safety profile is encouraging, showing potential for monthly dosing and convenient patient self-administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
-
Rhea-AI Summary
Skye Bioscience, Inc. (OTCQB: SKYE) Receives Request from OTC Markets Group Inc. for Statement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
Rhea-AI Summary
Skye Bioscience, Inc. (OTCQB: SKYE) and Tautomer Bioscience (Pty) Limited have announced an agreement granting Tautomer an exclusive license to develop and commercialize Skye's proprietary THC prodrug, SBI-100, as a novel suppository application for chronic intractable pain and other indications in South Africa and the rest of Africa. The agreement includes development milestones, sales milestones, and tiered double-digit royalties on net product sales. Tautomer will also purchase Skye shares in open market transactions. This partnership aims to address the unmet medical need for non-opioid alternatives for chronic pain in South Africa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
59.55%
Tags
none
-
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) has treated the first patient in its Phase 2 clinical trial evaluating SBI-100 Ophthalmic Emulsion’s ability to lower intraocular pressure, safety, and relevant biomarkers in patients with primary open-angle glaucoma or ocular hypertension. The Phase 2 study will compare two concentrations of SBI-100 OE vs. placebo, dosing twice a day for 14 days, with analysis of IOP data from 50% of patients enrolled to be performed in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) to present its glaucoma program at two ophthalmology-focused conferences, showcasing SBI-100 Ophthalmic Emulsion, a first-in-class CB1 agonist. The company will introduce recent Phase 1 data and discuss details of its Phase 2a clinical study. Executives will be available for 1x1 meetings at the BTIG 3rd Annual Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
conferences
Rhea-AI Summary
Skye Bioscience reports successful results from Phase 1 trial of SBI-100 OE, an ophthalmic drug targeting glaucoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.24%
Tags
-
Rhea-AI Summary
Skye Bioscience, Inc. announces 1-for-250 reverse stock split effective September 8th. Total issued and outstanding shares will be approximately 12,312,551. No fractional shares will be issued. Stockholders' ownership interest and voting power remain virtually unchanged.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none
-
Rhea-AI Summary
Skye Bioscience to present company overview at H.C. Wainwright 25th 3rd Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Skye Bioscience expands resources and technologies with acquisition of Bird Rock Bio, raising $17M in new capital. Plans to advance Phase 2a glaucoma clinical trial with nimacimab and expects Phase 1 results for SBI-100 Ophthalmic Emulsion by end of Q3 2023. Skye's cash and cash equivalents expected to fund operations into 2024. Goal to uplist to a national stock exchange with proposed reverse stock split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.75%
Tags
Skye Bioscience

OTC:SKYE

SKYE Rankings

SKYE Stock Data

44.45M
30.58M
1.32%
84.23%
7.14%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO